In these circumstances, glucagon secretion and pgc-1α are stimulated, and therefore, the effect obtained would be the re-induction of hepatic alas1. To avoid this effect in our study, AIP mice co-injected with fast-acting insulin received twice as many glucose doses as those treated with Ins-ApoAI, which would lead to an increased risk of weight gain if the protocol were repeated regularly. The gene discussed is APOA1; the disease is autoimmune pancreatitis.